The levels of IgG, IgA, IgM and CD8+ in the RA group and the SLE group after treatment were significantly lower than those before treatment, and the levels of CD3+, CD4+ and CD4+/CD8+ were significantly higher than those before treatment, with statistically significant differences (P<0.05). This evidence concerns the gene CD79A and rheumatoid arthritis.